Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Dyne Therapeutics, Inc. (DYN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.96+1.05 (+7.04%)
At close: 04:00PM EST
Advertisement

Dyne Therapeutics, Inc.

830 Winter Street
Waltham, MA 02451
United States
781 786 8230
http://www.dyne-tx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees71

Key Executives

NameTitlePayExercisedYear Born
Mr. Joshua T. BrummCEO, Pres & Director789.44kN/A1978
Dr. Romesh Subramanian Ph.D.Co-Founder & Advisor565.17kN/A1966
Ms. Susanna Gatti High M.B.A.Chief Operating Officer409.31kN/A1968
Mr. Gene KimVP of Fin.N/AN/A1977
Mr. Richard William ScalzoVP of Accounting & Admin. and TreasurerN/AN/A1986
Dr. Oxana Beskrovnaya Ph.D.Chief Scientific OfficerN/AN/A1961
Ms. Amy ReillyVP of Corp. Communications & Investor RelationsN/AN/A1974
Dr. Thomas-Christian Mix M.D., M.S.Sr. VP of Clinical Devel.N/AN/A1967
Ms. Debra FeldmanVP & Head of Regulatory AffairsN/AN/A1971
Mr. Daniel WilsonVP & Head of Intellectual PropertyN/AN/A1972
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.

Corporate Governance

Dyne Therapeutics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement